PILAR OBAT · PRIORITAS 2

715 obat layak dievaluasi untuk Fornas.

Obat yang ada di salah satu sumber bukti internasional (NICE Drug HTA atau WHO Essential Medicines List), namun BELUM di Fornas Indonesia. Satu sumber sudah cukup memberi sinyal bahwa drug ini layak dipertimbangkan — bukan urgent seperti Prioritas 1, tapi tetap masuk pipeline kaji-HTA.

715

Obat Prioritas 2

309

NICE only

406

WHO EML only

✗

Coverage Fornas (definisi P2)

Kriteria Prioritas 2 — obat memenuhi salah satu:

ada di NICE Drug HTA, tidak di WHO EML, belum di Fornas — banyak modern oncology biologics di sini (309 obat)
ada di WHO Essential Medicines List, tidak ada NICE TA, belum di Fornas — sering antibiotik klasik dan obat tropis (406 obat)

Logic: hanya satu sumber bukti internasional menyebut, jadi evidence base lebih tipis dibanding Prioritas 1. Tapi 715 obat ini masih merupakan gap nyata yang Indonesia perlu pertimbangkan kaji secara sistematis.

Distribusi

Per kelas ATC anatomi

715 obat tersebar di 14 kelas

Kelas ATC L1	Jumlah	% dari priority
Antineoplastic and immunomodulating agents	170	23.8%	chlormethine, treosulfan, carmustine, ...
Antiinfectives for systemic use	135	18.9%	doxycycline, tetracycline, tigecycline, ...
Alimentary tract and metabolism	72	10.1%	sodium fluoride, fluoride, chlortetracycline, ...
Nervous system	50	7.0%	diethyl ether, halothane, esketamine, ...
Blood and blood forming organs	47	6.6%	acenocoumarol, heparin, dalteparin, ...
Cardiovascular system	47	6.6%	digitoxin, quinidine, procainamide, ...
Antiparasitic products	33	4.6%	metronidazole, diloxanide, amodiaquine, ...
Dermatologicals	29	4.1%	miconazole, selenium sulfide, ciclopirox, ...
Genito-urinary system and sex hormones	26	3.6%	clotrimazole, tinidazole, ergometrine, ...
Sensory organs	25	3.5%	tetracycline, natamycin, erythromycin, ...
Various	25	3.5%	ipecacuanha, edetates, pralidoxime, ...
Respiratory system	24	3.4%	xylometazoline, budesonide, ciclesonide, ...
Systemic hormonal preparations	16	2.2%	somapacitan, somatrogon, carbetocin, ...
Musculo-skeletal system	16	2.2%	ibuprofen, penicillamine, alcuronium, ...

Kandidat advokasi paling kuat

Top 8 dengan NICE appraisal terbanyak

Multiple NICE appraisals = multiple indikasi yang dievaluasi cost-effective

L01XK01
olaparib
Antineoplastic and immunomodulating agents · source: NICE
8
NICE appraisals
L04AF03
upadacitinib
Antineoplastic and immunomodulating agents · source: NICE
7
NICE appraisals
D11AH05
dupilumab
Dermatologicals · source: NICE
6
NICE appraisals
L01EX07
cabozantinib
Antineoplastic and immunomodulating agents · source: NICE
6
NICE appraisals
L01XX44
aflibercept
Antineoplastic and immunomodulating agents · source: NICE
6
NICE appraisals
L01EX09
nintedanib
Antineoplastic and immunomodulating agents · source: NICE
5
NICE appraisals
L01XX52
venetoclax
Antineoplastic and immunomodulating agents · source: NICE
5
NICE appraisals
L04AF01
tofacitinib
Antineoplastic and immunomodulating agents · source: NICE
5
NICE appraisals

Daftar lengkap

Semua Prioritas 2

715 obat · instant search

715obat cocokmenampilkan 300 teratas

ATC	Nama generik	Kelas	NICE	EML	Fornas	e-Kat	Source combination	HTA priority
L01XK01	olaparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF03	upadacitinib	Antineoplastic and immunomodulating agents	●	○	○	●	NICE	Prioritas 2
D11AH05	dupilumab	Dermatologicals	●	○	○	○	NICE	Prioritas 2
L01EX07	cabozantinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX44	aflibercept	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX09	nintedanib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX52	venetoclax	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF01	tofacitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX05	regorafenib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX22	selpercatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FA03	obinutuzumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FF04	avelumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FG02	ramucirumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC16	guselkumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC18	risankizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC21	bimekizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF02	baricitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ02	ravulizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
R03DX09	mepolizumab	Respiratory system	●	○	○	○	NICE	Prioritas 2
A10AB01	insulin (human)	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
L01BC08	decitabine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CE01	topotecan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EM01	idelalisib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FC02	isatuximab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XG02	carfilzomib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XK02	niraparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BB06	darolutamide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BX04	relugolix	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC13	ixekizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG05	vedolizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ01	eculizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
M05BX04	denosumab	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
N03AX24	cannabidiol	Nervous system	●	○	○	○	NICE	Prioritas 2
R03DX05	omalizumab	Respiratory system	●	○	○	○	NICE	Prioritas 2
S01AD02	trifluridine	Sensory organs	●	○	○	○	NICE	Prioritas 2
S01LA09	faricimab	Sensory organs	●	○	○	○	NICE	Prioritas 2
A03AC02	dimethylaminopropionylphenothiazine	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AH01	methylnaltrexone bromide	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A08AA02	fenfluramine	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A08AA12	setmelanotide	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A10BK04	ertugliflozin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB14	sebelipase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
B02BX08	avatrombopag	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B03XA06	luspatercept	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AX05	exagamglogene autotemcel	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
G03XC01	raloxifene	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
G04BD12	mirabegron	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
H01CC04	linzagolix	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
J05AJ04	cabotegravir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX18	letermovir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX25	baloxavir marboxil	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
L01AB02	treosulfan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01AD01	carmustine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EA04	bosutinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01ED02	ceritinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01ED04	brigatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01ED05	lorlatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EM04	duvelisib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX01	sunitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX10	midostaurin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX14	entrectinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX18	avapritinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX13	enfortumab vedotin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX14	polatuzumab vedotin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX15	belantamab mafodotin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX17	sacituzumab govitecan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX18	amivantamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX27	epcoritamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX28	glofitamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XK03	rucaparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XK04	talazoparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL06	brexucabtagene autoleucel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL07	idecabtagene vicleucel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XM02	ivosidenib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX66	selinexor	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BB05	apalutamide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AA24	abatacept	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AA32	apremilast	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC14	sarilumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC24	mirikizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AE02	ozanimod	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF04	filgotinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG03	natalizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG04	belimumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ08	iptacopan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AX06	pomalidomide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
M05BX05	burosumab	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
M09AX02	chondrocytes, autologous	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
M09AX09	onasemnogene abeparvovec	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
N01AX14	esketamine	Nervous system	●	○	○	○	NICE	Prioritas 2
N02CD06	rimegepant	Nervous system	●	○	○	○	NICE	Prioritas 2
N06BA14	solriamfetol	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX18	vutrisiran	Nervous system	●	○	○	○	NICE	Prioritas 2
R03DX10	benralizumab	Respiratory system	●	○	○	○	NICE	Prioritas 2
S01LA06	brolucizumab	Sensory organs	●	○	○	○	NICE	Prioritas 2
V03AB38	andexanet alfa	Various	●	○	○	○	NICE	Prioritas 2
A01AA01	sodium fluoride	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A03BA04	belladonna total alkaloids	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A05AA04	obeticholic acid	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A05AX05	odevixibat	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A05AX06	elafibranor	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AH03	naloxegol	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AH05	naldemedine	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AX02	carbon dioxide producing drugs	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AX05	prucalopride	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A07AA11	rifaximin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AA07	metreleptin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB12	elosulfase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB13	asfotase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB15	velmanase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB17	cerliponase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB20	pegunigalsidase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB21	atidarsagene autotemcel	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB22	avalglucosidase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB23	cipaglucosidase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB24	pegzilarginase	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB25	olipudase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB26	eladocagene exuparvovec	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX07	sapropterin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX08	teduglutide	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX10	eliglustat	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX14	migalastat	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX16	givosiran	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX18	lumasiran	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX19	fosdenopterin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
B01AC22	prasugrel	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B01AC25	cangrelor	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B01AD11	tenecteplase	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B01AX07	caplacizumab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BD16	etranacogene dezaparvovec	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX04	romiplostim	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX07	lusutrombopag	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX09	fostamatinib	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX10	concizumab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX11	marstacimab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B03XA05	roxadustat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B03XA08	vadadustat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AC05	lanadelumab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AC06	berotralstat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AC07	garadacimab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AX04	mitapivat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
C01BB02	mexiletine	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01BD07	dronedarone	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01BG11	vernakalant	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01CX09	angiotensin ii	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01DX22	vericiguat	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01EB24	mavacamten	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01EB25	acoramidis	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C03DA05	finerenone	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C03XA01	tolvaptan	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C05BA04	pentosan polysulfate sodium	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C09DX04	valsartan and sacubitril	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C09XX01	sparsentan	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX09	ezetimibe	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX13	evolocumab	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX14	alirocumab	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX15	bempedoic acid	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX16	inclisiran	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX17	evinacumab	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX18	volanesorsen	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
D02BB02	afamelanotide	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D03AX13	betulae cortex	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D05AX06	roflumilast	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D10AX06	clascoterone	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH04	alitretinoin	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH06	crisaborole	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH08	abrocitinib	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH10	lebrikizumab	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH11	delgocitinib	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH12	nemolizumab	Dermatologicals	●	○	○	○	NICE	Prioritas 2
G02CX06	fezolinetant	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
G04BD15	vibegron	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
G04BE08	tadalafil	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
H01AC07	somapacitan	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H01AC08	somatrogon	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H02AB18	vamorolone	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H05AA04	abaloparatide	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H05BX01	cinacalcet	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H05BX04	etelcalcetide	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
J05AE30	nirmatrelvir and ritonavir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AF08	adefovir dipivoxil	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AP10	elbasvir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AP52	dasabuvir, ombitasvir, paritaprevir and ritonavir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX10	maribavir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX28	bulevirtide	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J06AA04	botulinum antitoxin	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J06BD03	tixagevimab and cilgavimab	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J07AP01	typhoid, oral, live attenuated	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
L01AA05	chlormethine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CA05	vinflunine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CD04	cabazitaxel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CX01	trabectedin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01DB11	pixantrone	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EA06	asciminib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EB07	dacomitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EE04	selumetinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EG01	temsirolimus	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EG04	sirolimus	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EH02	neratinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EH03	tucatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EJ02	fedratinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EJ04	momelotinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EK03	tivozanib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EK04	fruquintinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EL02	acalabrutinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EM03	alpelisib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EN01	erdafitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EN02	pemigatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EN04	futibatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EP01	capmatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EP02	tepotinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX02	sorafenib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX04	vandetanib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX11	quizartinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX12	larotrectinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX13	gilteritinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX19	ripretinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX23	pralsetinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX27	capivasertib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FA02	ofatumumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FB01	inotuzumab ozogamicin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FE03	necitumumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX02	gemtuzumab ozogamicin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX06	dinutuximab beta	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX08	elotuzumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX09	mogamulizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX12	tafasitamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX22	loncastuximab tesirine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX24	teclistamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX25	mosunetuzumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX29	talquetamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX31	zolbetuximab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX32	elranatamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX33	tarlatamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XD07	padeliporfin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XG03	ixazomib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XH03	panobinostat	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XJ01	vismodegib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XJ03	glasdegib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL02	talimogene laherparepvec	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL05	ciltacabtagene autoleucel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL09	tabelecleucel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL12	obecabtagene autoleucel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XM04	vorasidenib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX67	tagraxofusp	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX73	sotorasib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX74	belzutifan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX75	tebentafusp	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX77	adagrasib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BA04	elacestrant	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BX02	degarelix	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L03AX15	mifamurtide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L03AX22	leniolisib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AA41	imlifidase	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AA48	belumosudil	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC08	canakinumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC12	brodalumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC17	tildrakizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC19	satralizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC22	spesolimab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AD03	voclosporin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AE03	siponimod	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AE04	ponesimod	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AE05	etrasimod	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF07	deucravacitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF08	ritlecitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG06	alemtuzumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG11	anifrolumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG14	ublituximab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ03	pegcetacoplan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ05	avacopan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ07	crovalimab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ09	danicopan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AK02	teriflunomide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AL01	efgartigimod alfa	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AX05	pirfenidone	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AX08	darvadstrocel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AX09	diroximel fumarate	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
M05BX06	romosozumab	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
M09AX03	ataluren	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
M09AX07	nusinersen	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
N02CD07	atogepant	Nervous system	●	○	○	○	NICE	Prioritas 2
N03AX25	cenobamate	Nervous system	●	○	○	○	NICE	Prioritas 2
N03AX27	ganaxolone	Nervous system	●	○	○	○	NICE	Prioritas 2
N04BA07	foslevodopa and decarboxylase inhibitor	Nervous system	●	○	○	○	NICE	Prioritas 2
N04BB01	amantadine	Nervous system	●	○	○	○	NICE	Prioritas 2
N05AH01	loxapine	Nervous system	●	○	○	○	NICE	Prioritas 2
N05CF03	zaleplon	Nervous system	●	○	○	○	NICE	Prioritas 2
N05CJ03	daridorexant	Nervous system	●	○	○	○	NICE	Prioritas 2
N06AX22	agomelatine	Nervous system	●	○	○	○	NICE	Prioritas 2
N06AX26	vortioxetine	Nervous system	●	○	○	○	NICE	Prioritas 2
N06BX13	idebenone	Nervous system	●	○	○	○	NICE	Prioritas 2
N07BB05	nalmefene	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX02	riluzole	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX08	tafamidis	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX11	pitolisant	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX12	patisiran	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX21	eplontersen	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX25	omaveloxolone	Nervous system	●	○	○	○	NICE	Prioritas 2
R03DX08	reslizumab	Respiratory system	●	○	○	○	NICE	Prioritas 2